UnknownPhase 4

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

China10 participantsStarted 2014-10

Plain-language summary

This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-75 years old * Lung adenocarcinoma patients with epidermal growth factor receptor gene mutation,stage I-IIIB after surgery * The patients' Eastern Cooperative Oncology Group scores are ≤ 0-2 Exclusion Criteria: * Mismatch conditions above * Have used other anti-cancer therapy drug before the trial and may influence the outcome

What they're measuring

Recurrence-free Survival

Timeframe: 6 months

Trial details

NCT IDNCT02283424

SponsorChinese PLA General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-10

View on ClinicalTrials.gov More Neoplasms, Therapy-Associated trials